PF 708093Alternative Names: PF-708093
Latest Information Update: 11 Mar 2008
At a glance
- Originator Pfizer
- Class Antibacterials
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 20 Dec 2006 Phase-I clinical trials in Bacterial infections in USA (unspecified route)